CGEM earnings analysis
What we found in CGEM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cullinan Therapeutics reported a net loss of $49.7 million for Q1 2026 with basic diluted EPS of $(0.75). Cash and investments totaled $393.3 million, supporting operations through at least 2029. The recent FDA acceptance of their NDA for Zipalertinib is a significant milestone ahead of a target action date of February 27, 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Notable Cash Reserves
- The company ended the quarter with $393.3 million in cash and investments, offering a substantial runway.
- FDA NDA Acceptance
- The NDA for Zipalertinib was accepted by the FDA, with a target action date set for February 27, 2027.
- Reduction in Operating Expenses
- Operating expenses decreased from $54.996 million in Q1 2025 to $53.697 million in Q1 2026.
- Increased Interest Income
- Interest income was $4.098 million in Q1 2026, down from $6.580 million in Q1 2025.
- Stable R&D Expenses
- R&D expenses remained relatively stable, increasing slightly to $42.123 million from $41.459 million year-over-year.
- Strong Clinical Pipeline
- Continued advancement of several candidates, including CLN-978 and zipalertinib, noted in ongoing studies.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Net Losses
- Cullinan reported a net loss of $49.7 million for Q1 2026, continuing significant operating losses.
- Negative Cash Flow Impact
- Net cash used in operating activities was $46.045 million for Q1 2026, up from $43.155 million in Q1 2025.
- Dependency on Future Drug Approvals
- Future financial stability relies heavily on the success of ongoing clinical trials and future drug approvals.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.75
What they said about what is next.
The company has deferred numeric guidance to future announcements.
The filing reads better than the one before it.
What came before.
- 10-Q · May 15, 2024
- Cullinan reported a smaller loss in Q1 2024 with net loss of $37,340 (in thousands) and EPS of $(0.86), an improvement versus net loss $58,141 and EPS $(1.42) in Q1 2023. Operating expenses fell notably as R&D declined…
- 10-Q · August 10, 2023
- Cullinan reported a Q2 net loss of $32,214 (in thousands) / GAAP EPS of $(0.82) for the three months ended June 30, 2023 versus net income of $174,065 (in thousands) / EPS $3.90 in Q2 2022 — the swing largely reflects…
- 10-Q · November 9, 2021
- Cullinan Oncology reported a Q3 2021 net loss of $18.259 million (three months ended Sept. 30, 2021) and loss per share of $(0.40), while recognizing no revenue in the quarter. The company materially strengthened its…
- 10-Q · August 10, 2021
- Cullinan Oncology reported Q2 2021 net loss per share of $(0.36) on license revenue of $0.0; net loss attributable to common stockholders was $(15,636) for the quarter. Operating expenses rose to $16,604 (from $14,122)…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CGEM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever